Evommune

IPO initial public offering markets raise financing
Biotech

Inflammation biotech Evommune eyes IPO to fund dermatitis trials

Evommune has become the latest indicator that drug developers are once again tempted by the public markets.
James Waldron Oct 10, 2025 6:35am
amplitude

Canadian VC Amplitude unveils $192M biotech fund

May 29, 2024 10:30am
US dollar bills scattered on a yellow background undefined undefinedGetty Images

Pivotal bioVenture Partners unveils $389M fund

Dec 18, 2023 7:00am
Eczema

Evommune drops IRAK4 inhibitor on phase 2 dermatitis data

Sep 27, 2023 10:30am